CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响

doi:10.3969/j.issn.1004-616x.2024.01.009

癌变·畸变·突变 ›› 2024, Vol. 36 ›› Issue (1): 53-57,65.doi: 10.3969/j.issn.1004-616x.2024.01.009

CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响

黄丛改, 刘清, 郑树涛, 刘涛, 谭依依, 彭天元, 陈娇, 卢晓梅

新疆医科大学第一附属医院, 省部共建中亚高发病成因与防治国家重点实验室, 新疆乌鲁木齐 830011

收稿日期:2023-11-01 修回日期:2023-12-02 出版日期:2024-02-19 发布日期:2024-02-19
通讯作者: 卢晓梅
作者简介:黄丛改,E-mail:huangconggai66@163.com。
基金资助:
国家自然科学基金（82260568）；新疆维吾尔自治区“天山英才”科技创新领军人才项目（2022TSYCLJ0031）；省部共建国家重点实验室项目（SKL-HIDCA-2022-14，SKL-HIDCA-2020-JZ2）

Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells

HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei

The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi 830011, Xinjiang, China

Received:2023-11-01 Revised:2023-12-02 Online:2024-02-19 Published:2024-02-19

摘要/Abstract

摘要： 目的：探讨CXC受体2（CXCR2）在食管鳞癌组织中的表达及其对食管癌细胞生物学行为的影响。方法：收集手术切除的食管鳞癌组织74例作为研究组，其配对的癌旁正常食管组织74例作为对照组，采用免疫组织化学染色检测CXCR2的表达，比较研究组与对照组间CXCR2表达水平的差异，分析CXCR2表达及其与临床病理特征的关系。并采用CCK-8试剂盒、平板集落形成实验、细胞迁移和侵袭实验检测CXCR2拮抗剂SCH527123对食管癌细胞KYSE30生物学行为的影响。结果：与对照组比较，CXCR2在食管鳞癌研究组中的阳性表达率为73.0%（54/74），明显高于对照组13.5%（10/74），差异具有统计学意义（χ²=53.298，P=0.000）。CXCR2的表达与食管鳞癌分化程度和淋巴结转移密切相关（χ²=5.515，P=0.019；χ²=7.320，P=0.007）；与患者性别、年龄、肿瘤部位、肿瘤大体分型、肿瘤直径、浸润深度、脉管瘤栓及神经侵犯均无明显相关关系（P>0.05）。在体外细胞实验中，与对照组相比，CXCR2拮抗剂SCH527123显著抑制食管癌细胞KYSE30的增殖、迁移和侵袭（均为P<0.05）。结论：CXCR2在食管鳞癌组织中表达上调且与患者的不良预后相关，CXCR2拮抗剂SCH527123可以抑制食管癌细胞的增殖、迁移和侵袭，推测CXCR2可能是食管癌潜在的预测和靶向治疗的分子标志物。

关键词: CXCR2, 食管癌, 临床意义, 病理特征, 靶向治疗, 生物学行为

Abstract: OBJECTIVE: To investigate expression of the CXC receptor 2(CXCR2) in esophageal squamous cell carcinoma(ESCC) tissues and its impact on the biological behavior of esophageal cancer cells.METHODS: A total of 74 cases of surgically removed ESCC tissues were collected as the study group and 74 cases of paired adjacent normal esophageal tissues were collected as the control group. CXCR2 expression was detected by immunohistochemical staining, and the difference of CXCR2 expression level between the study and the control groups was compared, and the relationship between CXCR2 expression and clinicopathological characteristics was analyzed. The effects of CXCR2 antagonist SCH527123 on the biological behavior of esophageal cancer cells KYSE30 were examined by CCK-8 cell proliferation, plate colony formation, cell migration and invasion assay. RESULTS: The positive expression rate of CXCR2 in ESCC was 73.0%(54/74), which was significantly higher than the 13.5%(10/74) in the adjacent normal tissues(χ²=53.298, P=0.000). Significant differences were also detected in relation to the differentiation degree and lymph node metastasis of ESCC(χ²=5.515, P=0.019; χ²=7.320, P=0.007). However, the expression was not significantly related to gender, age, tumor location, gross classification of tumor, tumor diameter, depth of invasion, vessel emboli and nerve invasion(P>0.05). In the KYSE30 cells, application of the antagonist SCH527123 significantly inhibited their proliferation, migration, and invasion. CONCLUSION: CXCR2 expression was up regulated in ESCC tissues and was associated with poor prognosis of patients.CXCR2 antagonist SCH527123 inhibited the proliferation, migration, and invasion of esophageal cancer cells in vitro. CXCR2 may therefore be a molecular marker for molecular prediction and targeted therapy of esophageal cancer.

Key words: CXCR2, esophageal squamous cell carcinoma, clinical significance, pathological features, targeted therapy, biological behavior

中图分类号:

R979.1

黄丛改, 刘清, 郑树涛, 刘涛, 谭依依, 彭天元, 陈娇, 卢晓梅. CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响[J]. 癌变·畸变·突变, 2024, 36(1): 53-57,65.

HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei. Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 53-57,65.

参考文献

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2] XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022:profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5):584-590.
[3] ROGERS J E, SEWASTJANOW-SILVA M, WATERS R E, et al. Esophageal cancer:emerging therapeutics[J]. Expert Opin Ther Targets, 2022, 26(2):107-117.
[4] LAZENNEC G, RAJARATHNAM K, RICHMOND A. CXCR2chemokine receptor-a master regulator in cancer and physiology[J]. Trends Mol Med, 2024, 30(1):37-55.
[5] ZHANG Y L, CAO H J, HAN X, et al. Chemokine receptor CXCR-2 initiates atrial fibrillation by triggering monocyte mobilization in mice[J]. Hypertension, 2020, 76(2):381-392.
[6] PAWLUCZUK E,ŁUKASZEWICZ-ZAJĄC M, MROCZKO B.The role of chemokines in the development of gastric cancerdiagnostic and therapeutic implications[J]. Int J Mol Sci, 2020,21(22):8456.
[7] WU K, CUI L L, YANG Y, et al. Silencing of CXCR2 and CXCR7 protects against esophageal cancer[J]. Am J Transl Res, 2016, 8(8):3398-3408.
[8] SUI P, HU P P, ZHANG T H, et al. High expression of CXCR-2 correlates with lymph node metastasis and predicts unfavorable prognosis in resected esophageal carcinoma[J].Med Oncol, 2014, 31(2):809.
[9] 曹旬旬,费素娟.食管癌患者肿瘤组织CXCL5和CXCR2的表达与病情和预后的相关性分析[J].中华消化病与影像杂志:电子版, 2023, 13(5):299-304.
[10] 范玉宏,周海丰,范爽,等. CXCR-2在食管鳞癌组织中的表达及其与MMP-9、VEGF的相关性研究[J].癌变·畸变·突变, 2021, 33(3):225-229, 240.
[11] NISHI T, TAKEUCHI H, MATSUDA S, et al. CXCR2expression and postoperative complications affect long-term survival in patients with esophageal cancer[J]. World J Surg Oncol, 2015, 13:232.
[12] CHAPMAN R W, MINNICOZZI M, CELLY C S, et al. A novel,orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation[J]. J Pharmacol Exp Ther, 2007, 322(2):486-493.
[13] SHANG F M, LI J. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway[J]. Med Clin, 2019, 152(11):425-430.
[14] ZHANG R J, ROQUE D M, READER J, et al. Combined inhibition of IL-6 and IL-8 pathways suppresses ovarian cancer cell viability and migration and tumor growth[J]. Int J Oncol, 2022, 60(5):50.
[15] FU S L, CHEN X, LIN H J, et al. Inhibition of interleukin 8/C-X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells[J]. Int J Oncol, 2018,53(1):349-357.
[16] NING Y, LABONTE M J, ZHANG W, et al. The CXCR2antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models[J]. Mol Cancer Ther, 2012, 11(6):1353-1364.
[17] INFANGER D W, CHO Y, LOPEZ B S, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche[J]. Cancer Res, 2013, 73(23):7079-7089.
[18] YANG X Y, CHEN X J, ZHANG S S, et al. Collagen1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer[J].Cell Rep, 2023, 42(10):113270.
[19] OGURA M, TAKEUCHI H, KAWAKUBO H, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma[J]. Surgery, 2013, 154(3):512-520.
[20] 隋萍.趋化因子受体CXCR-2在食管癌组织中的表达及与淋巴结转移对指导预后的临床意义[D].济南:山东大学,2014.

CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响

Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛松, 胡加海, 董祥宁. PGAM5在胰腺癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2024, 36(1): 29-34.
[2]	王科芳, 陈瑜, 吴陈雨, 刘梅, 汪丽杰, 田建广, 周小会, 许岚. 白细胞介素-17A与雌激素受体α和β在上皮性卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2024, 36(1): 42-47.
[3]	刘志彬, 岳文涛. Notch信号通路在卵巢癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 473-476.
[4]	赵立然, 卜梁. 生物信息学分析食管癌关键基因的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(5): 374-381.
[5]	闫俊涛, 李洪霖, 朱亚辉, 常思思, 高付彦, 马纯政. 食管癌干细胞特性及相关蛋白的研究进展[J]. 癌变·畸变·突变, 2023, 35(3): 228-230.
[6]	曹国栋, 曹芳. PI3K/AKT/mTOR信号通路及相关表观遗传调控机制在结直肠癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(2): 148-153.
[7]	路大鹏, 赵卫林, 王玉强, 路洪超, 魏双平. 食管癌生存随访调查及列线图预后预测模型的建立[J]. 癌变·畸变·突变, 2023, 35(1): 37-42.
[8]	王婷, 张雯雯, 张永欣, 曾勇, 王俊玲, 李成云. miR-101基因簇与食管癌发病风险的病例对照研究[J]. 癌变·畸变·突变, 2022, 34(4): 273-278.
[9]	冯志寅, 吴怡娴, 哈晓丹, 陈邬锦, 李秀梅, 董娟娟. 食管癌高发人群血浆游离DNA中的p38MAPK基因检测研究[J]. 癌变·畸变·突变, 2022, 34(2): 105-109.
[10]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[11]	张娜, 范志露, 杨荔艳, 常晨, 蔡岩, 郝佳洁, 王明荣. 食管鳞癌中SERPINB5表达降低的作用机制及其临床意义[J]. 癌变·畸变·突变, 2021, 33(2): 101-109.
[12]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[13]	陈婉娴, 王思梦, 陈张瑜, 王潘集, 郑淳文, 李恩民, 许丽艳. CDC42抑制剂CASIN对食管癌细胞活力与迁移能力的抑制作用[J]. 癌变·畸变·突变, 2021, 33(2): 136-142.
[14]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[15]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.